UPDATE: Jefferies Raises PT on AbbVie on Attractive Valuation
April 10, 2013 at 12:10 PM EDT
In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV ), and raised the price target from $45.00 to $50.00. In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the
